Clinical Trial of Allogeneic Mesenchymal Stem Cell Therapy for Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients Unresponsive to Rituximab and Intravenous Immunoglobulin

<div>Renal function over time from 6 months before MSC treatment to 6 months after the final infusion. M: months; RTX: rituximab; IVIG: intravenous immunoglobulin; MSCs: mesenchymal stem cells; Tx: treatment.</div>

Stem Cells International

fig2

Figure 2

Figure 2: Clinical Trial of Allogeneic Mesenchymal Stem Cell Therapy for Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients Unresponsive to Rituximab and Intravenous Immunoglobulin 

Figure 2 | Clinical Trial of Allogeneic Mesenchymal Stem Cell Therapy for Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients Unresponsive to Rituximab and Intravenous Immunoglobulin 